REUTERS 10/03/21 Antibiotics may have been overused in COVID-19 patients: U.S. study. J Glob Antimicrob Resist. 2021 Mar 1 AMR research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic. CLINICAL MICROBIOLOGY AND INFECTION 01/02/21 Effect of the COVID-19 pandemic on antibiotic use in primary care.
INFECTIOUS DISEASE NEWS 07/01/21 Fills for 10 most common antibiotics declined up to 56% in early days of pandemic. January 07, 2021 2 min read Source/Disclosures Disclosures: Clancy reports numerous ties to industry.
Please see the study for all other authors’ relevant financial disclosures. Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Prescription fills for each of the 10 most prescribed outpatient antibiotics in the United States declined by up to 56% in April during the first peak of the COVID-19 pandemic, researchers found. Fills for seven of the antibiotics rebounded by July. “We previously published a paper on the impact of COVID-19 on in-hospital antibiotic prescribing and stewardship at our health care system. “The impact of this usage on antimicrobial resistance remains unclear,” Clancy said. Cornelius (Neil) J. Clancy and colleagues obtained monthly prescription fill data for August 2014 through July 2020 from the IQVIA National Prescription Audit databases. EUROSURVEILLANCE 12/11/20 Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance?
FRONT. VET. SCI. 09/10/20 Antimicrobial Resistance in Agri-Food Chain and Companion Animals as a Re-emerging Menace in Post-COVID Epoch: Low-and Middle-Income Countries Perspective and Mitigation Strategies. Introduction Human and animal populations are at risk of cross-transmission of zoonotic bacteria via direct contact due to close proximity with food animals, companion animals, live wildlife markets, environmental contamination, and the intake of contaminated animal origin food items.
THE LANCET 29/09/20 Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election. Globally, the USA has recorded the highest number of COVID-19 cases and deaths, WHOWHO coronavirus disease (COVID-19) dashboard. and still needs to simultaneously respond to another looming potential pandemic.
The rise in multidrug-resistant bacterial infections that are undetected, undiagnosed, and increasingly untreatable threatens the health of people in the USA and globally. In 2020 and beyond, we cannot afford to ignore antimicrobial resistance (AMR). Bacterial infections unsuccessfully treated due to AMR claim at least 700 000 lives per year worldwide and are projected to be associated with the deaths of 10 million people per year by 2050, at a cost of US$100 trillion to the global economy through loss of productivity. L'OPINION_MA 23/09/20 Les dangers démultipliés de l’antibiorésistance en période de Covid.
Alors que dans notre pays, la pandémie fait plus de ravages que jamais et que les services de réanimation fonctionnent à plein régime, se pose la question des facteurs qui peuvent perturber l’immunité et le cas échéant rendre un antibiotique inefficace face un germe résistant.
Il y a quelques jours, nous avions consacré sur ces mêmes colonnes un dossier sur les maladies nosocomiales, c’est-à-dire contractées dans les hôpitaux. Le Dr Mohamed Khatouf, professeur de réanimation et chef du service de réanimation du CHU de Fès, nous avait alors expliqué que, comparativement à l’Europe, le Maroc n’était pas touché aussi fortement par l’apparition de germes résistant aux antibiotiques, mais que cette problématique était présente et qu’elle devenait de plus en plus préoccupante, surtout dans les grands services de réanimation. Un problème mondial À l’origine de l’antibiorésistance, il y a le mauvais usage des antibiotiques chez les humains mais également chez l’animal.
Oussama ABAOUSS. NATURE 20/05/20 Antimicrobial resistance in the age of COVID-19. Action is needed to prevent COVID-19 from casting a long shadow over antimicrobial resistance.
A peek under the hood of studies reporting on patients hospitalized with coronavirus disease 2019 (COVID-19) reveals widespread use of antimicrobial therapies as part of the package of clinical care in some countries. For example, in a retrospective cohort analysis of 191 patients from two hospitals in Wuhan, Zhou et al. write that 95% of patients were treated with antibiotics and 21% were treated with antivirals1. But practises differ around the world. A retrospective case series of 393 patients in New York revealed that only 5.6% of patients had bacteraemia and none of them received antibiotics2. In a recent letter, Cox et al. highlighted a need to prospectively monitor coinfections in patients with COVID-19 to understand whether coinfection affects disease progression, and to enable antimicrobial stewardship3. References 1.Zhou, F. et al. Download references About this article. CONTAGIONLIVE 31/08/20 Antimicrobial Use in COVID-19 Patients.
Since the SARS-CoV-2/COVID-19 pandemic, we have been learning at a rapid pace.
From testing to immunity and even isolation precautions, this has been a “build the bridge as you walk across” situation. One piece to this is also patient care and the medical management of those hospitalized with COVID-19. Increasingly, there have been concerns about antimicrobial stewardship during COVID-19 response, as the “use everything but the kitchen sink” approach is easily deployed during novel and emergent times. While COVID-19 is a novel disease, antimicrobial resistance is not. The Centers for Disease Control and Prevention (CDC) reported that in the United States alone, someone gets a resistant infection every 11 seconds and every 15 minutes, someone dies as a result of their antimicrobial-resistant infection. For those reported infections, there are 3 million cases in the U.S. each year and 48,000 related deaths. FRONT. VET. SCI. 30/07/20 Antimicrobial resistance in agri-food chain and companion animals as a re-emerging menace in post-COVID epoch: low-and middle-income countries perspective and mitigation strategies.
1West Bengal University of Animal and Fishery Sciences, India 2Indian Veterinary Research Institute (IVRI), India Antimicrobial resistance (AMR) leads to enormous financial losses associated with high morbidity, mortality, man day loss, hospital length of stay, health-care and social costs.
In human, over prescription of antimicrobials, which is presumably higher during COVID, is identified as the major source of selection for antimicrobial resistant bacteria but use of antimicrobials in food animals, poultry, companion animals, fishes and vegetables and moreover, environmental resistance gene pool also play an important role. OMS - 2020 - Tackling antimicrobial resistance in the COVID-19 pandemic. HEALTHLINE 23/06/20 Drug-Resistant Bacteria Can Be Hidden Danger for People with COVID-19. Superinfections are a common complication in which a secondary bacterial infection occurs on top of the primary viral infection.People who have prolonged stays in the intensive care unit (ICU), like those with COVID-19 who can be hospitalized for weeks, are prone to secondary infections.
Suggests that about 50 percent of people who’ve died from COVID-19 also had a secondary bacterial or fungal infection. COVID-19 has already killed over 473,000 people, but medical experts are learning more about how the disease can lead to death. Superinfections — a common complication in which a secondary bacterial infection occurs on top of the primary viral infection — are also to blame. SCIENCEMAG 16/04/20 Antibiotic treatment for COVID-19 complications could fuel resistant bacteria. Science’s COVID-19 reporting is supported by the Pulitzer Center.
In her regular job, Priya Nori runs Montefiore Medical Center’s antibiotic stewardship program, and spends most of her time ensuring that the Bronx-based hospital doesn’t overuse the drugs and allow bacteria resistant to them to thrive. But like many physicians, Nori is now spending all of her time helping treat COVID-19 patients at her New York City hospital, which like other medical centers in the pandemic hot spot, is crowded with 50% more patients than normal. As part of that care, she and other doctors are administering many more antibiotics than normal, which is a recipe for the rapid rise or spread of resistant bacteria, especially given the crowded conditions. Antibiotics do not directly affect SARS-CoV-2, the respiratory virus responsible for COVID-19, but viral respiratory infections often lead to bacterial pneumonia. Physicians can struggle to tell which pathogen is causing a person’s lung problems. Related.
PEW 27/04/20 How COVID-19 Is Increasing Antibiotic Use. In the span of just a few short months, the ramifications and impact of COVID-19 have been vast.
Virtually every aspect of public health has been affected by this pandemic, and the fight against antibiotic-resistant bacteria is no exception. Recently, Pew examined the invaluable role that antibiotics play in modern health care—during the pandemic and beyond. Our analysis was just one way to look at the issues at the intersection of antibiotic resistance and the rapid spread of the novel coronavirus, and there are countless more. Here are several articles published elsewhere that explore the nexus of two critical concerns: limiting the impact of COVID-19 and preserving the effectiveness of essential antibiotics.
Together, these articles underscore the critical role of antibiotics and the need to take immediate steps to address antibiotic resistance to ensure the best care for patients today and in the future. McMaster UNIVERSITY 20/04/20 Drug-resistant superbugs: A global threat intensified by the fight against coronavirus. Methicillin-resistant Staphylococcus aureus (MRSA) bacteria (coloured yellow) enmeshed within a human white blood cell (coloured red). MRSA is a major cause of hospital-associated infections. (NIAID photo) Lori L. Burrows is a professor of biochemistry and biomedical sciences. This article is republished from The Conversation under a Creative Commons license. LE DEVOIR 02/05/20 La lutte contre l’antibiorésistance et les leçons de la pandémie.